Synergistic dietary supplement compositions for the prevention, treatment or control of inflammatory disorders
An herbal composition, comprising a therapeutically effective amount of an extract of Terminalia chebula; a therapeutically effective amount of an extract of Curcuma longa; and a therapeutically effective amount of a non-acidic, water-immiscible organic solvent extract of a Boswellia serrata resin.
1. An herbal composition, comprising:
from 20% by weight to 75% by weight of an extract of Terminalia chebula;
from 10% by weight to 40% by weight of an extract of Curcuma longa ; and
from 10% by weight to 40% by weight of a non-acidic, water-immiscible organic solvent extract of a Boswellia serrata resin,
based on the total weight of the Terminalia chebula, Curcuma longa , and Boswellia serrata extracts.
2. The composition according to claim 1 , wherein the non-acidic, water-immiscible organic solvent extract of the Boswellia serrata resin is obtained by:
extracting Boswellia serrata gum resin with a water-immiscible organic solvent to obtain an organic solution;
extracting the organic solution with aqueous alkali to remove boswellic acids from the organic solution; and
removing the water-immiscible organic solvent from the organic solution to obtain an organic solvent extract.
3. The composition according to claim 1 , wherein the non-acidic, water-immiscible organic solvent extract of the Boswellia serrata resin is obtained by:
extracting Boswellia serrata gum resin with a water-immiscible organic solvent to obtain an organic solution;
extracting the organic solution with aqueous alkali to remove boswellic acids from the organic solution;
removing the water-immiscible organic solvent from the organic solution to obtain an organic solvent extract; and
removing volatile components from the organic solvent extract under vacuum to obtain said non-acidic, water-immiscible organic solvent extract.
4. The composition according to claim 1 , wherein the composition further comprises at least one ingredient selected from the group consisting of:
plant derived anti-inflammatory agents,
pharmaceutically, nutraceutically, or dietetically acceptable carriers, and
pharmaceutically, nutraceutically, or dietetically acceptable excipients.
5. The composition according to claim 1 , wherein:
the extract of Terminalia chebula is prepared from dried fruits of Terminalia chebula by extraction with an aqueous, alcoholic or hydroalcoholic solvent;
the extract of Curcuma longa is prepared from dried rhizomes of Curcuma longa by extraction with an aqueous, alcoholic or hydroalcoholic solvent; and
the non-acidic, water-immiscible organic solvent extract of the Boswellia serrata resin is prepared from a gum resin of Boswellia serrata.
6. The composition according to claim 4 , wherein the carriers and excipients are selected from the group consisting of surfactants, binders, diluents, disintegrants, lubricants, preservatives, stabilizers, buffers, suspensions, and drug delivery systems.
7. The composition according to claim 1 , wherein the composition further comprises:
from 0% by weight to 20% by weight of a Boswellia serrata extract which contains at least 5% 3-O-acetyl-11-keto-β-boswellic acid (AKBA),
based on the total weight of the Terminalia chebula, Curcuma longa , and Boswellia serrata extracts.
8. The composition according to claim 5 , wherein the composition comprises:
from 20% by weight to 75% by weight of the extract of Terminalia chebula;
from 15% by weight to 40% by weight of the extract of Curcuma longa ; and
from 10% by weight to 40% by weight of the non-acidic, water-immiscible organic solvent extract of the Boswellia serrata resin; and
from 0% by weight to 20% by weight of a Boswellia serrata extract which contains at least 5% 3-O-acetyl-11-keto-β-boswellic acid (AKBA),
based on the total weight of the Terminalia chebula, Curcuma longa , and Boswellia serrata extracts.
9. The composition according to claim 1 , wherein the composition comprises:
from 25% by weight to 65% by weight of the extract of Terminalia chebula;
from 12% by weight to 30% by weight of the extract of Curcuma longa ; and
from 12% by weight to 30% by weight of the non-acidic, water-immiscible organic solvent extract of the Boswellia serrata resin, based on the weight of the composition.
10. The composition according to claim 1 , wherein the composition comprises:
from 25% by weight to 45% by weight of the extract of Terminalia chebula;
from 15% by weight to 25% by weight of the extract of Curcuma longa;
from 15% by weight to 25% by weight of the non-acidic, water-immiscible organic solvent extract of the Boswellia serrata resin, and
from 15% by weight to 25% by weight of a Boswellia serrata extract which contains at least 5% 3-O-acetyl-11-keto-β-boswellic acid (AKBA), based on the weight of the composition.
11. The composition according to claim 1 , wherein the extracts of Terminalia chebula, Curcuma longa and Boswellia serrata are aqueous, alcoholic or hydroalcoholic extracts.
12. The composition according to claim 1 , wherein the composition is formulated to be administered orally, topically, transdermally or parenterally.
13. A dosage form, comprising the herbal composition of claim 1 ,
wherein said dosage form is a tablet, a capsule, a pill, a cream, an emulsion, or a suppository.
14. A dosage form, comprising a first anti-inflammatory herbal composition and a second herbal composition, wherein:
a) said first herbal composition consists of:
from 20% by weight to 75% by weight of an extract of Terminalia chebula , based on the weight of the first herbal composition;
from 15% by weight to 40% by weight of an extract of Curcuma long , based on the weight of the first herbal composition; and
from 10% by weight to 40% by weight of a non-acidic, water-immiscible organic solvent extract of the Boswellia serrata resin, based on the weight of the first herbal composition; and
b) said second herbal composition comprises:
up to 20% by weight of a Boswellia serrata extract which contains at least 5% 3-O-acetyl-11-keto-β-boswellic acid (AKBA), based on the combined weight of the first herbal composition and the second herbal composition.
15. The dosage form according to claim 13 , further comprising at least one plant derived anti-inflammatory agent.
16. An herbal composition effective for treatment of inflammation, comprising:
from 20% by weight to 75% by weight of an aqueous alcoholic or hydroalcoholic extract of dried fruits of Terminalia chebula;
from 15% by weight to 40% by weight of an aqueous alcoholic or hydroalcoholic extract of dried rhizomes of Curcuma longa ; and
from 10% by weight to 40% by weight of a non-acidic, water-immiscible organic solvent extract of a Boswellia serrata resin,
wherein all percentages are based on the combined weight of the Terminalia chebula, Curcuma longa , and Boswellia serrata extracts.